Growth differentiation factor 11 regulates high glucose-induced cardiomyocyte pyroptosis and diabetic cardiomyopathy by inhibiting inflammasome activation

Jing Zhang, Guolong Wang, Yuxuan Shi, Xin Liu, Shuang Liu, Wendi Chen, Yunna Ning, Yongzhi Cao, Yueran Zhao, Ming LiCardiovascular 2024 · DOI

TL;DR

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes, often involving heart cell death called pyroptosis. This study reveals that Growth Differentiation Factor 11 (GDF11) can protect against DCM by inhibiting pyroptosis. The research uncovers a novel pathway (PPARα-GDF11-ASC) that GDF11 uses to exert its protective effects, offering new therapeutic avenues for DCM.

What Problem Does This Paper Address?

Diabetes is a chronic condition that can lead to numerous complications, one of the most severe being diabetic cardiomyopathy (DCM). DCM is characterized by structural and functional abnormalities in the heart, ultimately leading to heart failure. While the exact mechanisms are still being unraveled, inflammation and programmed cell death, specifically pyroptosis, have emerged as key players in DCM progression. Pyroptosis is a highly inflammatory form of cell death that can exacerbate tissue damage. Growth Differentiation Factor 11 (GDF11), a protein known for its roles in various physiological processes, has shown promise in cardiovascular health, but its specific role in mitigating pyroptosis in the context of DCM remained unclear. This paper aims to elucidate GDF11's mechanism of action in preventing high glucose-induced cardiomyocyte pyroptosis and its potential as a therapeutic target for DCM.

Methods

The researchers employed a multi-pronged approach using both in vitro and in vivo models.

  • Diabetic Mouse Model: Type 1 diabetes was induced in C57BL/6J mice using streptozotocin (STZ) injections. To investigate GDF11's role, some mice were engineered to overexpress GDF11 using adeno-associated virus 9 (AAV9) delivered intravenously.
  • Cardiomyocyte Culture: H9c2 rat cardiomyocyte cell line was used to create an in vitro model of diabetes by culturing them in high glucose (50 mM) medium.
  • Pyroptosis Assessment: Pyroptosis was evaluated using propidium iodide (PI) staining to detect cell membrane integrity and by measuring the expression of key pyroptosis-related proteins (GSDMD-N, c-Caspase-1, IL-1β, ASC, NLRP3) via Western blotting and ELISA.
  • Inflammasome Inhibition: To confirm the role of the inflammasome, ASC was silenced using small interfering RNA (siRNA).
  • GDF11 Manipulation: GDF11 was overexpressed using a plasmid and its effects were assessed. Conversely, GDF11 was knocked down using siRNA to observe the consequences.
  • Protein Interaction Studies: Co-immunoprecipitation assays were used to confirm the direct binding between GDF11 and ASC, as well as between GDF11 and PPARα.
  • Cardiac Function Assessment: Echocardiography was performed to evaluate left ventricular function (LVEF, FS, LVIDd, etc.) in the different mouse groups.
  • Histological Analysis: Hematoxylin and eosin (H&E) and Masson's trichrome staining were used to assess myocardial morphology and fibrosis. Immunohistochemistry was employed to visualize specific protein expressions.
  • Proteomic Analysis: Mass spectrometry was used for proteomic analysis of heart tissues to identify differentially expressed proteins and pathways.
  • PPARα Modulation: The role of PPARα was investigated by using a PPARα agonist and by silencing PPARα using siRNA.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from in vitro cell cultures and in vivo animal models.

Key Insights and Ideas

  • GDF11 as a Pyroptosis Inhibitor in DCM: The study provides strong evidence that GDF11 can significantly reduce high glucose-induced pyroptosis in both cardiomyocytes and in the hearts of diabetic mice. This is a crucial finding, as pyroptosis is a major contributor to DCM pathology.
  • GDF11 Directly Binds to ASC: A key mechanistic insight is the direct interaction between GDF11 and ASC, a critical adaptor protein in inflammasome assembly. This binding appears to prevent the formation and activation of the inflammasome, thereby halting the pyroptosis cascade.
  • The PPARα-GDF11-ASC Axis: The research uncovers a novel regulatory pathway where PPARα negatively regulates GDF11 expression. Under high glucose conditions, PPARα activation leads to decreased GDF11, promoting pyroptosis. Conversely, GDF11 can inhibit pyroptosis by interacting with ASC. This interplay highlights a complex regulatory network in DCM.
  • PPARα Agonism Worsens DCM: The study demonstrates that activating PPARα exacerbates cardiac dysfunction, fibrosis, and pyroptosis in DCM models, even in the presence of GDF11. This suggests that targeting PPARα might be counterproductive for DCM treatment.
  • Therapeutic Potential of GDF11: The findings strongly suggest that enhancing GDF11 levels, particularly in the heart, could be a promising therapeutic strategy for preventing or treating diabetic cardiomyopathy.

Key Results

  • GDF11 Downregulation in DCM: GDF11 protein levels were found to be significantly decreased in the hearts of diabetic mice and in high glucose-treated cardiomyocytes.
  • GDF11 Overexpression Ameliorates DCM: In diabetic mice, AAV9-mediated GDF11 overexpression improved cardiac function (e.g., increased LVEF, FS), reduced myocardial fibrosis, and decreased pyroptosis markers.
  • GDF11 Inhibits Pyroptosis In Vitro: Overexpression of GDF11 in H9c2 cells treated with high glucose reduced PI-positive cells and suppressed the expression of pyroptosis-related proteins.
  • ASC is Essential for Pyroptosis: Silencing ASC significantly reduced high glucose-induced pyroptosis in cardiomyocytes.
  • PPARα Inhibits GDF11 and Promotes Pyroptosis: Knockdown of PPARα in cardiomyocytes increased GDF11 expression and reduced pyroptosis. Conversely, PPARα overexpression decreased GDF11 and increased pyroptosis.
  • GDF11 and PPARα Interaction: GDF11 and PPARα were shown to interact, with their binding increasing under high glucose conditions, suggesting a mutual inhibitory relationship.

Limitations and Future Work

  • Age and Disease State: The authors acknowledge that GDF11's role in cardiac injury can be complex and may depend on factors like age and the specific disease state. While this study focuses on DCM, further investigation into GDF11's impact across different age groups and chronic vs. acute conditions is warranted.
  • Systemic vs. Myocardial GDF11: The study emphasizes the importance of myocardial-specific GDF11 expression, suggesting that much of the existing literature might have focused on systemic GDF11, potentially leading to conflicting results. Future work could further explore the differential effects of systemic versus cardiac-specific GDF11 modulation.
  • Clinical Translation: While the findings are promising for therapeutic development, the study is preclinical. Further research is needed to translate these findings into effective clinical treatments for DCM patients.
  • Broader Inflammasome Involvement: While the study focused on ASC, the authors speculate that multiple inflammasomes are involved in DCM. Future research could explore the specific roles of other inflammasome components and their interaction with GDF11.

Summary updated

Abstract

These findings demonstrate that GDF11 can treat diabetic cardiomyopathy by alleviating pyroptosis and reveal the role of the PPARα-GDF11-ASC pathway in DCM, providing ideas for new strategies for cardioprotection.
BibTeX
@inproceedings{zhang2024growth,
  author = {Jing Zhang and Guolong Wang and Yuxuan Shi and Xin Liu and Shuang Liu and Wendi Chen and Yunna Ning and Yongzhi Cao and Yueran Zhao and Ming Li},
  title = {{Growth differentiation factor 11 regulates high glucose-induced cardiomyocyte pyroptosis and diabetic cardiomyopathy by inhibiting inflammasome activation}},
  booktitle = {Cardiovascular},
  year = {2024},
  doi = {10.1186/s12933-024-02258-3},
}
Figure